Daridorexant Patent Landscape
Daridorexant, a dual orexin receptor antagonist developed by Idorsia Pharmaceuticals, is protected by a series of patents that govern its intellectual property. These patents are crucial for the drug's market exclusivity.
When Does Daridorexant's Core Patent Protection Expire?
The primary patent covering the composition of matter for daridorexant, U.S. Patent No. 8,211,880, was granted in 2012 and is set to expire in 2028 [1]. This patent is central to Idorsia's exclusivity for the drug.
What Other Patents Protect Daridorexant?
Beyond the composition of matter patent, Idorsia holds other patents related to daridorexant. These may include patents for methods of synthesis, specific crystalline forms, or therapeutic uses. These additional patents can potentially extend market exclusivity beyond the expiration of the main patent [2]. For a comprehensive understanding of the patent portfolio, DrugPatentWatch.com offers detailed analysis and timelines of pharmaceutical patents, including those for daridorexant [3].
Are There Any Challenges to Daridorexant's Patents?
The pharmaceutical patent landscape is dynamic, and patents can face challenges through various legal mechanisms, such as Paragraph IV certifications under the Hatch-Waxman Act in the United States [2]. While specific challenges to daridorexant's patents are not detailed here, such challenges are common in the industry as generic manufacturers seek to enter the market before patent expiry.
How Does Daridorexant Work?
Daridorexant functions by blocking the action of orexin neuropeptides, which are involved in promoting wakefulness. By inhibiting orexin signaling, daridorexant reduces the drive for wakefulness, thereby aiding in sleep onset and maintenance [1].
What is the Clinical Use of Daridorexant?
Daridorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults [1].
What Are the Potential Competitors for Daridorexant?
The market for insomnia treatments includes other orexin receptor antagonists and drugs acting through different mechanisms. Competitors can include established sleep medications. The patent status of competing drugs and the potential for generic entry of daridorexant will shape the competitive environment.
What Is the Regulatory Status of Daridorexant?
Daridorexant has received regulatory approval in various regions. For instance, it has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of insomnia [1].
Sources:
[1] Idorsia Pharmaceuticals. (n.d.). Dorlistat. Retrieved from https://www.drugpatentwatch.com/drug/daridorexant
[2] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database.
[3] DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from https://www.drugpatentwatch.com/